A Phase 1 interventional study of Docetaxel and RhuMab 2C4 in Solid Tumor, sponsored by Hoffmann-La Roche. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-17.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4 (Perjeta) and docetaxel (Taxotere) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Docetaxel · Drug: RhuMab 2C4
Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Docetaxel · Drug: RhuMab 2C4
Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
Drug: Docetaxel · Drug: RhuMab 2C4
Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Also known as: Taxotere
Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Also known as: Omnitarg
Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab
A prior dose level was defined as an MTD if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs). If there were no DLTs or DLTs were seen in less than (\<) 2 participants in the highest dose level, that was considered as MTD. Participants received escalating doses of docetaxel and pertuzumab until DLTs were observed. DLTs were defined as any of the following: 1) Any non-hematological toxicity ≥ Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.
Time frame: Cycle 1 Up to Day 15
Plasma Decay Half Life (t1/2) for Pertuzumab in Combination With Docetaxel
The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity.
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Maximum Observed Plasma Concentration (Cmax) for Pertuzumab in Combination With Docetaxel
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as micrograms per milliliter (μg/mL).
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Area Under the Concentration Curve From Time Zero to the Last Visit (AUC [0-last]) for Pertuzumab in Combination With Docetaxel
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (μg\*day/mL).
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
AUC From Time Zero to Infinity (AUC [0-infinity]) for Pertuzumab in Combination With Docetaxel
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as μg\*day/mL.
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Clearance (Cl) of Pertuzimab in Combination With Docetaxel
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Volume of Distribution (Vz) at Steady State of Pertuzumab in Combination With Docetaxel
The volume of distribution at steady state (Vz), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Mean Residence Time (MRT) of Pertuzumab
MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.
Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Percentage of Participants by Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
Best Overall response was evaluated as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). CR: complete disappearance of all target lesions. PR: at least a 30 percent (%) decrease in the sum of the longest diameters. SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameters since the treatment started. PD: at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.
Time frame: Weeks 7 (Cycle 2),13 (Cycle 4) and Final Visit Up to 22 weeks
Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) by Category of Decrease and Timepoint
Ejection fraction (EF) is the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a person's cardiac function. Changes in LVEF were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria. The decrease in LVEF has been categorized as follows: A) Increase, no change, decrease from baseline less than (\<) 10%; B) Absolute value \<50% and decrease from baseline greater than or equal to (≥) 10%; C) Absolute value \<50% and decrease from baseline≥15% ; D) Other. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.
Time frame: Baseline, Weeks 7(Cycle 2), 13 (Cycle 4) and Final Visit Up to Week 22
t1/2 for Docetaxel Alone and in Combination With Pertuzumab
The biological half-life or terminal half-life of docetaxel is the time in hours it takes for it to lose half of its pharmacologic activity. Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Tmax for Docetaxel Alone and in Combination With Pertuzumab
Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. When the rate of absorption equals the rate of elimination. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Cmax for Docetaxel Alone and in Combination With Pertuzumab
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
AUC(0-∞) for Docetaxel Alone and in Combination With Pertuzumab
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as ng\*h/mL. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Vss for Docetaxel Alone and in Combination With Pertuzumab
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
CL for Docetaxel Alone and in Combination With Pertuzumab
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per hour per meter squared (mL/h/m\^2). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Number of Participants With DLTs
DLTs were defined as any of the following: 1) Any non-hematological toxicity greter than or equal to (≥) Grade 3 according t0 CTCAE version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.
Time frame: From Baseline until 4 weeks after the end of treatment
| Milestone | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| Started | 6 | 2 | 6 | 5 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 2 | 6 | 5 |
| Withdrew: Adverse event | 2 | 1 | 0 | 1 |
| Withdrew: Insufficient therapeutic response | 2 | 0 | 2 | 2 |
| Withdrew: Refused treatment | 1 | 0 | 0 | 0 |
| Withdrew: Completed 6 cycles of therapy | 1 | 1 | 4 | 2 |
| Milestone | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| Started | 1 | 0 | 3 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 3 | 1 |
| Withdrew: Insufficient therapeutic response | 1 | 0 | 2 | 0 |
| Withdrew: Refused treatment | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
A prior dose level was defined as an MTD if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs). If there were no DLTs or DLTs were seen in less than (\<) 2 participants in the highest dose level, that was considered as MTD. Participants received escalating doses of docetaxel and pertuzumab until DLTs were observed. DLTs were defined as any of the following: 1) Any non-hematological toxicity ≥ Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.
| mg/m^2 | Entire Study Population |
|---|---|
| Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab | 75.0 |
The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity.
| days | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 12.65 (7.80 to 19.59) | 11.65 (6.95 to 25.96) | NA (NA to NA) |
| Cycle 2 (n=7,0,10) | 19.02 (9.02 to 49.63) | NA (NA to NA) | 18.46 (8.85 to 42.00) |
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as micrograms per milliliter (μg/mL).
| μg/mL | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 301.0 ± 93.0 | 255.0 ± 84.0 | NA ± NA |
| Cycle 2 (n=7,0,10) | 368.0 ± 79.0 | NA ± NA | 150.0 ± 43.0 |
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (μg\*day/mL).
| μg*day/mL | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 2390 ± 584 | 1749 ± 543 | NA ± NA |
| Cycle 2 (n=7,0,10) | 3500 ± 551 | NA ± NA | 1491 ± 472 |
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as μg\*day/mL.
| μg*day/mL | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 3951 ± 919 | 2796 ± 967 | NA ± NA |
| Cycle 2 (n=7,0,10) | 6856 ± 2335 | NA ± NA | 2762 ± 892 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
| mL/day | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 282 ± 83 | 329 ± 97 | NA ± NA |
| Cycle 2 (n=7,0,10) | 167 ± 49 | NA ± NA | 169 ± 60 |
The volume of distribution at steady state (Vz), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.
| mL | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 5214 ± 1386 | 5355 ± 1680 | NA ± NA |
| Cycle 2 (n=7,0,10) | 4672 ± 1221 | NA ± NA | 4233 ± 1555 |
MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.
| days | Pertuzumab 1050 | Pertuzumab 840 | Pertuzumab 420 |
|---|---|---|---|
| Cycle 1 (n=8,11,0) | 17.8 ± 5.8 | 15.8 ± 6.7 | NA ± NA |
| Cycle 2 (n=7,0,10) | 29.5 ± 18.5 | NA ± NA | 25.8 ± 13.2 |
Best Overall response was evaluated as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). CR: complete disappearance of all target lesions. PR: at least a 30 percent (%) decrease in the sum of the longest diameters. SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameters since the treatment started. PD: at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.
| percentage of participants | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| Cycle 2: CR (n=6,1,6,4) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 2:PR (n=6,1,6,4) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 2:SD (n=6,1,6,4) | 83.3 | 100.0 | 83.3 | 75.0 |
| Cycle 2:PD (n=6,1,6,4) | 16.7 | 0 | 16.7 | 25.0 |
| Cycle 2:Missing (n=6,1,6,4) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 4:CR (n=5,1,5,3) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 4:PR (n=5,1,5,3) | 0.0 | 0.0 | 20.0 | 0 |
| Cycle 4:SD (n=5,1,5,3) | 80.0 | 100.0 | 40.0 | 66.7 |
| Cycle 4:PD (n=5,1,5,3) | 20.0 | 0.0 | 40.0 | 33.3 |
| Cycle 4:Missing (n=5,1,5,3) | 0.0 | 0.0 | 0.0 | 0.0 |
| Final visit:CR (n=6,2,6,5) | 0.0 | 0.0 | 0.0 | 0.0 |
| Final visit:PR (n=6,2,6,5) | 0.0 | 0.0 | 16.7 | 0.0 |
| Final visit:SD (n=6,2,6,5) | 33.3 | 50.0 | 33.3 | 20.0 |
| Final visit:PD (n=6,2,6,5) | 50.0 | 0.0 | 50.0 | 60.0 |
| Final visit:Missing (n=6,2,6,5) | 16.7 | 50.0 | 0.0 | 20.0 |
Ejection fraction (EF) is the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a person's cardiac function. Changes in LVEF were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria. The decrease in LVEF has been categorized as follows: A) Increase, no change, decrease from baseline less than (\<) 10%; B) Absolute value \<50% and decrease from baseline greater than or equal to (≥) 10%; C) Absolute value \<50% and decrease from baseline≥15% ; D) Other. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.
| percentage of participants | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| Cycle 2: A (n=6,1,6,4) | 83.3 | 100.0 | 100.0 | 100.0 |
| Cycle 2: B (n=6,1,6,4) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 2: C (n=6,1,6,4) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 2: D (n=6,1,6,4) | 16.7 | 0.0 | 0.0 | 0.0 |
| Cycle 4: A (n=5,1,4,3) | 100.0 | 100.0 | 75.0 | 100.0 |
| Cycle 4: B (n=5,1,4,3) | 0.0 | 0.0 | 25.0 | 0.0 |
| Cycle 4: C (n=5,1,4,3) | 0.0 | 0.0 | 0.0 | 0.0 |
| Cycle 4: D (n=5,1,4,3) | 0.0 | 0.0 | 0.0 | 0.0 |
| Final Visit: A (n=3,1,5,2) | 66.7 | 100.0 | 80.0 | 100.0 |
| Final Visit: B (n=3,1,5,2) | 0.0 | 0.0 | 0.0 | 0.0 |
| Final Visit: C (n=3,1,5,2) | 0.0 | 0.0 | 0.0 | 0.0 |
| Final Visit: D (n=3,1,5,2) | 33.3 | 0.0 | 20.0 | 0.0 |
The biological half-life or terminal half-life of docetaxel is the time in hours it takes for it to lose half of its pharmacologic activity. Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| days | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75+ Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 17.7 (7.31 to 22.7) | NA (NA to NA) | 12.0 (9.56 to 19.4) | NA (NA to NA) | 8.92 (7.49 to 13.5) | NA (NA to NA) |
| Cycle 2(n=0,6,0,6,0,4) | NA (NA to NA) | 19.7 (12.5 to 27.1) | NA (NA to NA) | 13.8 (9.62 to 23.8) | NA (NA to NA) | 11.8 (8.04 to 21.4) |
Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. When the rate of absorption equals the rate of elimination. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| days | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 0.50 (0.50 to 0.90) | NA (NA to NA) | 0.50 (0.50 to 0.90) | NA (NA to NA) | 0.90 (0.90 to 0.90) | NA (NA to NA) |
| Cycle 2 (n=0,6,0,6,0,4) | NA (NA to NA) | 0.90 (0.50 to 1.25) | NA (NA to NA) | 0.90 (0.50 to 0.90) | NA (NA to NA) | 0.70 (0.50 to 0.90) |
Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| ng/mL | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 1642 ± 274 | NA ± NA | 3128 ± 895 | NA ± NA | 5450 ± 1867 | NA ± NA |
| Cycle 2 (n=0,6,0,6,0,4) | NA ± NA | 1695 ± 331 | NA ± NA | 2722 ± 912 | NA ± NA | 4705 ± 1871 |
The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as ng\*h/mL. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| ng*h/mL | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 1838 ± 244 | NA ± NA | 3744 ± 1304 | NA ± NA | 5930 ± 2137 | NA ± NA |
| Cycle 2 (n=0,6,0,6,0,4) | NA ± NA | 1734 ± 409 | NA ± NA | 3496 ± 1211 | NA ± NA | 5218 ± 2216 |
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| mL/m^2 | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 786981 ± 218139 | NA ± NA | 410174 ± 184216 | NA ± NA | 254233 ± 85054 | NA ± NA |
| Cycle 2 (n=0,6,0,6,0,4) | NA ± NA | 1023569 ± 335711 | NA ± NA | 566759 ± 361946 | NA ± NA | 428863 ± 283977 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per hour per meter squared (mL/h/m\^2). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.
| mL/h/m^2 | Docetaxel 60 Alone | Docetaxel 60 + Pertuzumab 1050 | Docetaxel 75 Alone | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 Alone | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|---|---|
| Cycle 1 (n=6,0,6,0,5,0) | 33128 ± 4396 | NA ± NA | 22013 ± 7031 | NA ± NA | 18913 ± 7245 | NA ± NA |
| Cycle 2 (n=0,6,0,6,0,4) | NA ± NA | 35813 ± 6216 | NA ± NA | 23747 ± 8175 | NA ± NA | 22976 ± 12679 |
DLTs were defined as any of the following: 1) Any non-hematological toxicity greter than or equal to (≥) Grade 3 according t0 CTCAE version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.
| number of participants | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| Number of Participants With DLTs | 0 | 2 | 0 | 2 |
Collected over Adverse events were continuously monitored from Screening until 4 weeks after the final visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel 60 Plus (+) Pertuzumab 1050 | — | 3/6 (50%) | 6/6 (100%) |
| Docetaxel 75 + Pertuzumab 1050 | — | 2/2 (100%) | 2/2 (100%) |
| Docetaxel 75 + Pertuzumab 420 | — | 0/6 (0%) | 6/6 (100%) |
| Docetaxel 100 + Pertuzumab 420 | — | 3/5 (60%) | 5/5 (100%) |
| Event | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/2 | 0/6 | 0/5 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 1/2 | 0/6 | 1/5 |
| FatigueGeneral disorders | 0/6 | 1/2 | 0/6 | 0/5 |
| NauseaGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 1/5 |
| VomitingGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 1/5 |
| PyrexiaGeneral disorders | 1/6 | 0/2 | 0/6 | 0/5 |
| Lower respiratory tract infectionInfections and infestations | 1/6 | 0/2 | 0/6 | 0/5 |
| Urinary tract infectionInfections and infestations | 1/6 | 0/2 | 0/6 | 0/5 |
| ParalysisNervous system disorders | 1/6 | 0/2 | 0/6 | 0/5 |
| HypertensionVascular disorders | 1/6 | 0/2 | 0/6 | 0/5 |
| Event | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/6 | 2/2 | 5/6 | 4/5 |
| NauseaGastrointestinal disorders | 5/6 | 2/2 | 5/6 | 4/5 |
| FatigueGeneral disorders | 5/6 | 2/2 | 6/6 | 5/5 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/6 | 0/2 | 5/6 | 4/5 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/6 | 0/2 | 5/6 | 1/5 |
| Abdominal painGastrointestinal disorders | 4/6 | 0/2 | 0/6 | 2/5 |
| DysgeusiaNervous system disorders | 4/6 | 1/2 | 4/6 | 0/5 |
| RashSkin and subcutaneous tissue disorders | 4/6 | 0/2 | 2/6 | 2/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/6 | 0/2 | 4/6 | 1/5 |
| StomatitisGastrointestinal disorders | 1/6 | 0/2 | 0/6 | 3/5 |
The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication.
| Age, Continuous(years) | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 | Total |
|---|---|---|---|---|---|
| Mean | 58.2 ± 5.38 | 62.5 ± 9.19 | 59.5 ± 6.06 | 45.0 ± 20.21 | 55.6 ± 12.55 |
| Sex: Female, Male(Participants) | Docetaxel 60 Plus (+) Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 1050 | Docetaxel 75 + Pertuzumab 420 | Docetaxel 100 + Pertuzumab 420 | Total |
|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 3 | 6 |
| Male | 4 | 2 | 5 | 2 | 13 |
The record gives a start of Feb 2004, a primary completion of Apr 2006 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 9 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab